Developer docs
API playgroundTry for free, no card

Search company profiles

KeifeRx

Full company profile

uuid00031w2

Namestring
KeifeRx
Legal namestring
KeifeRx, LLC
Websiteurl
keiferx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

KeifeRx is a privately held, clinical-stage biopharmaceutical company developing orally delivered, second-generation kinase inhibitors as disease-modifying treatments for neurodegenerative illnesses. Its pipeline centers on four drug candidates — KFRX03 (lead asset for Alzheimer's disease, entering Phase 1 enrollment in 2026), KFRX04 (ALS, IND-enabling), KFRX05 (Parkinson's disease, co-development), and KFRX06 (Parkinson's disease via LRRK2 inhibition, preclinical) — designed for high blood-brain-barrier penetration and selective inhibition of validated kinases including c-ABL, c-KIT (mutants), DDR-1, LRRK2, and PIKfyve. The therapeutic hypothesis is that restoring autophagy while simultaneously reducing microglial-mediated neuroinflammation, clearing toxic proteins (alpha-synuclein, tau, amyloid), and repairing vascular damage can slow or reverse cognitive and motor decline. The company's intellectual property is grounded in an exclusive licensing agreement with Georgetown University, originally built on the clinical research of co-founder Charbel Moussa (MBBS, PhD), whose nilotinib Phase 2 trials demonstrated blood-brain-barrier penetration and biomarker effects in Alzheimer's and Lewy Body Dementia.

The company does not currently generate revenue and has no commercial products; its economic model is licensing and co-development partnerships with larger pharmaceutical companies. The lead example is the January 2026 research collaboration and option agreement with Amneal Pharmaceuticals for KFRX06. The company was founded in 2017 (corporate records) / 2019 (firmographic data) in McLean, Virginia, USA, completed a $6 million Series A financing in December 2021, and operates with 1–10 employees. Leadership comprises CEO Chris Hoyt, co-founders Charbel Moussa (Chair, Scientific Advisory Board) and Fernando L. Pagan (MD, FAAN, Director), with a Scientific Advisory Board of internationally recognized neurologists and dementia researchers. The company markets itself primarily through scientific conferences (Sachs Neuroscience Forum, Biotech Showcase, J.P. Morgan Healthcare Conference Week), peer-reviewed publications (notably the Journal of Clinical Medicine), and PR distribution via Business Wire and EIN Presswire.

Short descriptiontext

KeifeRx is a clinical-stage biopharmaceutical company developing orally delivered, second-generation kinase inhibitors for neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and frontotemporal dementia, with plans to monetize via licensing and co-development partnerships with larger pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMclean, United States
HQ citystring
Mclean
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kinase inhibitors, neurodegenerative disease therapeutics, clinical-stage biopharmaceutical, central nervous system drugs, oral small molecule therapy
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Neurodegenerative Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Licensing
TypeLicensing Royalties
Description

As a clinical-stage biopharmaceutical company, KeifeRx does not currently generate revenue. The company is developing a pipeline of drug candidates for neurodegenerative diseases and plans to commercialize through licensing agreements or co-development partnerships with larger pharmaceutical companies. The Amneal partnership for KFRX06 represents an example of this licensing/collaboration strategy.

keiferx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

KeifeRx develops a pipeline of orally delivered, second-generation small-molecule kinase inhibitors targeting neurodegenerative diseases, with lead asset KFRX03 in Phase 1 for Alzheimer's disease and additional preclinical candidates for Parkinson's disease (KFRX05, KFRX06), ALS (KFRX04), and frontotemporal dementia. The drug candidates are designed to cross the blood-brain barrier, restore autophagy, and simultaneously address neuroinflammation, toxic protein accumulation, and vascular damage. The company intends to commercialize its candidates through licensing or co-development agreements with larger pharmaceutical partners rather than direct sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 trial of nilotinib in Dementia with Lewy Bodies published in Journal of Clinical Medicine (June 2025), demonstrating safety and efficacy
+2 more records
Product overview1 text field

KeifeRx is a clinical-stage biopharmaceutical company developing a pipeline of orally delivered, second-generation kinase inhibitors for neurodegenerative diseases. The company's product portfolio centers on four drug candidates: KFRX03 (lead asset for Alzheimer's disease, Phase 1), KFRX04 (for ALS, IND-enabling), KFRX05 (for Parkinson's disease, co-development), and KFRX06 (for Parkinson's disease and frontotemporal dementia, preclinical). These drug candidates are designed for superior brain penetration and selective kinase inhibition to restore autophagy, clear toxic proteins, reduce neuroinflammation, and repair vascular damage. KFRX03, KFRX04, KFRX05, and KFRX06 represent a next-generation approach to treating dementia and neurodegenerative diseases by targeting c-ABL, c-KIT, LRRK2, DDR-1, and PIKfyve.

Product and service4 records
1KFRX03
CategoryCore product
Description

KeifeRx's lead asset and first-in-class small molecule kinase inhibitor for the treatment of Alzheimer's disease. It is highly brain penetrant with strong target engagement and a dose-dependent PD/PK relationship. KFRX03 targets c-ABL, c-KIT, and DDR-1, and has demonstrated a compelling safety profile with strong therapeutic benefit in mouse models of dementia.

2KFRX04
CategoryCore product
Description

A kinase inhibitor candidate for the treatment of ALS (amyotrophic lateral sclerosis). KFRX04 targets c-KIT and PIKfyve and is currently in the IND-enabling stage of development.

3KFRX05
CategoryCore product
Description

A kinase inhibitor candidate for Parkinson's disease. KFRX05 targets c-ABL and c-KIT (mutants) and is currently in the co-development opportunity stage.

4KFRX06
CategoryCore product
Description

A brain-penetrant LRRK2 inhibitor program for Parkinson's disease, also targeting c-ABL and c-KIT. KFRX06 is in preclinical development and is the subject of a research collaboration and option agreement with Amneal Pharmaceuticals announced in January 2026.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

KeifeRx entered into a research collaboration and option agreement with Amneal Pharmaceuticals (NASDAQ:AMRX) to advance KFRX06, a preclinical candidate targeting Parkinson's disease through KeifeRx's LRRK2 inhibitor technology. Financial terms were not disclosed. Amneal, with approximately $4.1-4.2 billion market capitalization and $2.93 billion trailing twelve-month revenue, will lead research to generate pre-IND data. The collaboration establishes a structured path for potential next-stage development and commercialization pending promising results.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing small molecules for Alzheimer's, Parkinson's, and other neurodegenerative diseases, with a similar mechanism-focused approach and comparable pipeline stage.

TypeBroad incumbent
Description

Established large-cap biopharmaceutical company with multiple approved and late-stage Alzheimer's therapies (e.g., lecanemab partnership with Eisai), representing the dominant incumbent in the neurodegenerative space KeifeRx targets.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's, with a complementary but partially overlapping pipeline approach.

TypeDirect peer
Description

CNS-focused biotech with FDA-approved neurology product and pipeline targeting brain disorders, comparable in scale and clinical stage to KeifeRx's neurodegenerative focus.

TypeDirect peer
Description

Biotech developing therapies for neurodegenerative diseases including Parkinson's and Alzheimer's, sharing a similar target-patient population and protein-clearance therapeutic thesis.

TypeDirect peer
Description

Clinical-stage neurodegenerative disease company developing small molecules targeting toxic protein aggregation in Alzheimer's disease and dementia with Lewy bodies, overlapping directly with KeifeRx's indication focus.

TypeBroad incumbent
Description

Larger CNS-focused biopharma developing therapies across multiple neurological indications, representing an established CNS pipeline competitor with broader resources.

TypeDirect peer
Description

Clinical-stage company developing therapeutics for neurodegenerative diseases including Parkinson's and ALS, with kinase and LRRK2 programs that overlap directly with KeifeRx's mechanism focus.

9Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotechnology company focused on Alzheimer's disease, with a small-molecule pipeline that addresses neurodegeneration through a similar mechanism-driven approach.

10Bristol Myers Squibb
TypeOthers
Description

Markets nilotinib (the drug KeifeRx's chemistry builds upon) and is active in neurodegeneration R&D, making it both a potential comparator and a future competitor or partner in the kinase-inhibitor neurodegeneration space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KeifeRx

Neurodegenerative Disease Therapeuticskeiferx.com

KeifeRx is a clinical-stage biopharmaceutical company developing orally delivered, second-generation kinase inhibitors for neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and frontotemporal dementia, with plans to monetize via licensing and co-development partnerships with larger pharmaceutical companies.

What KeifeRx does

KeifeRx is a privately held, clinical-stage biopharmaceutical company developing orally delivered, second-generation kinase inhibitors as disease-modifying treatments for neurodegenerative illnesses. Its pipeline centers on four drug candidates — KFRX03 (lead asset for Alzheimer's disease, entering Phase 1 enrollment in 2026), KFRX04 (ALS, IND-enabling), KFRX05 (Parkinson's disease, co-development), and KFRX06 (Parkinson's disease via LRRK2 inhibition, preclinical) — designed for high blood-brain-barrier penetration and selective inhibition of validated kinases including c-ABL, c-KIT (mutants), DDR-1, LRRK2, and PIKfyve. The therapeutic hypothesis is that restoring autophagy while simultaneously reducing microglial-mediated neuroinflammation, clearing toxic proteins (alpha-synuclein, tau, amyloid), and repairing vascular damage can slow or reverse cognitive and motor decline. The company's intellectual property is grounded in an exclusive licensing agreement with Georgetown University, originally built on the clinical research of co-founder Charbel Moussa (MBBS, PhD), whose nilotinib Phase 2 trials demonstrated blood-brain-barrier penetration and biomarker effects in Alzheimer's and Lewy Body Dementia.

The company does not currently generate revenue and has no commercial products; its economic model is licensing and co-development partnerships with larger pharmaceutical companies. The lead example is the January 2026 research collaboration and option agreement with Amneal Pharmaceuticals for KFRX06. The company was founded in 2017 (corporate records) / 2019 (firmographic data) in McLean, Virginia, USA, completed a $6 million Series A financing in December 2021, and operates with 1–10 employees. Leadership comprises CEO Chris Hoyt, co-founders Charbel Moussa (Chair, Scientific Advisory Board) and Fernando L. Pagan (MD, FAAN, Director), with a Scientific Advisory Board of internationally recognized neurologists and dementia researchers. The company markets itself primarily through scientific conferences (Sachs Neuroscience Forum, Biotech Showcase, J.P. Morgan Healthcare Conference Week), peer-reviewed publications (notably the Journal of Clinical Medicine), and PR distribution via Business Wire and EIN Presswire.

KeifeRx firmographics

Firmographics
Name
KeifeRx
Legal name
KeifeRx, LLC
Website
https://keiferx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
KeifeRx is a clinical-stage biopharmaceutical company developing orally delivered, second-generation kinase inhibitors for neurodegenerative diseases including Alzheimer's, Parkinson's, ALS, and frontotemporal dementia, with plans to monetize via licensing and co-development partnerships with larger pharmaceutical companies.
Ownership category
akta.pro rank

KeifeRx industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Kinase inhibitors
  • Neurodegenerative disease therapeutics
  • Clinical-stage biopharmaceutical
  • Central nervous system drugs
  • Oral small molecule therapy

Where KeifeRx is headquartered

Location

Headquarters

HQ city
Mclean
HQ country
United States
HQ region
North America

Offices1 record

Markets served

KeifeRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Licensing: As a clinical-stage biopharmaceutical company, KeifeRx does not currently generate revenue. The company is developing a pipeline of drug candidates for neurodegenerative diseases and plans to commercialize through licensing agreements or co-development partnerships with larger pharmaceutical companies. The Amneal partnership for KFRX06 represents an example of this licensing/collaboration strategy.

Go-to-market motion1 record

Marketing channels4 records

KeifeRx product offering

Product offering

Core offering

KeifeRx develops a pipeline of orally delivered, second-generation small-molecule kinase inhibitors targeting neurodegenerative diseases, with lead asset KFRX03 in Phase 1 for Alzheimer's disease and additional preclinical candidates for Parkinson's disease (KFRX05, KFRX06), ALS (KFRX04), and frontotemporal dementia. The drug candidates are designed to cross the blood-brain barrier, restore autophagy, and simultaneously address neuroinflammation, toxic protein accumulation, and vascular damage. The company intends to commercialize its candidates through licensing or co-development agreements with larger pharmaceutical partners rather than direct sales.

Product overview

KeifeRx is a clinical-stage biopharmaceutical company developing a pipeline of orally delivered, second-generation kinase inhibitors for neurodegenerative diseases. The company's product portfolio centers on four drug candidates: KFRX03 (lead asset for Alzheimer's disease, Phase 1), KFRX04 (for ALS, IND-enabling), KFRX05 (for Parkinson's disease, co-development), and KFRX06 (for Parkinson's disease and frontotemporal dementia, preclinical). These drug candidates are designed for superior brain penetration and selective kinase inhibition to restore autophagy, clear toxic proteins, reduce neuroinflammation, and repair vascular damage. KFRX03, KFRX04, KFRX05, and KFRX06 represent a next-generation approach to treating dementia and neurodegenerative diseases by targeting c-ABL, c-KIT, LRRK2, DDR-1, and PIKfyve.

Differentiator

Problem solved

Functional benefit

Products and services

  • KFRX03 KeifeRx's lead asset and first-in-class small molecule kinase inhibitor for the treatment of Alzheimer's disease. It is highly brain penetrant with strong target engagement and a dose-dependent PD/PK relationship. KFRX03 targets c-ABL, c-KIT, and DDR-1, and has demonstrated a compelling safety profile with strong therapeutic benefit in mouse models of dementia.
  • KFRX04 A kinase inhibitor candidate for the treatment of ALS (amyotrophic lateral sclerosis). KFRX04 targets c-KIT and PIKfyve and is currently in the IND-enabling stage of development.
  • KFRX05 A kinase inhibitor candidate for Parkinson's disease. KFRX05 targets c-ABL and c-KIT (mutants) and is currently in the co-development opportunity stage.
  • KFRX06 A brain-penetrant LRRK2 inhibitor program for Parkinson's disease, also targeting c-ABL and c-KIT. KFRX06 is in preclinical development and is the subject of a research collaboration and option agreement with Amneal Pharmaceuticals announced in January 2026.

Quantifiable outcome

  • Phase 2 trial of nilotinib in Dementia with Lewy Bodies published in Journal of Clinical Medicine (June 2025), demonstrating safety and efficacy
  • +2 more outcomes

Companies that use KeifeRx

Customer profile

Segments1 record

Ideal customer profiles2 records

KeifeRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

KeifeRx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Amneal PharmaceuticalscoreStrategic or Co-development Partner · 9 January 2026KeifeRx entered into a research collaboration and option agreement with Amneal Pharmaceuticals (NASDAQ:AMRX) to advance KFRX06, a preclinical candidate targeting Parkinson's disease through KeifeRx's LRRK2 inhibitor technology. Financial terms were not disclosed. Amneal, with approximately $4.1-4.2 billion market capitalization and $2.93 billion trailing twelve-month revenue, will lead research to generate pre-IND data. The collaboration establishes a structured path for potential next-stage development and commercialization pending promising results.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

KeifeRx competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Clinical-stage biotech developing small molecules for Alzheimer's, Parkinson's, and other neurodegenerative diseases, with a similar mechanism-focused approach and comparable pipeline stage.
  • Sage Therapeutics: CNS-focused biotech with FDA-approved neurology product and pipeline targeting brain disorders, comparable in scale and clinical stage to KeifeRx's neurodegenerative focus.
  • Prothena: Biotech developing therapies for neurodegenerative diseases including Parkinson's and Alzheimer's, sharing a similar target-patient population and protein-clearance therapeutic thesis.
  • Cognition Therapeutics: Clinical-stage neurodegenerative disease company developing small molecules targeting toxic protein aggregation in Alzheimer's disease and dementia with Lewy bodies, overlapping directly with KeifeRx's indication focus.
  • Denali Therapeutics: Clinical-stage company developing therapeutics for neurodegenerative diseases including Parkinson's and ALS, with kinase and LRRK2 programs that overlap directly with KeifeRx's mechanism focus.
  • Cassava Sciences: Clinical-stage biotechnology company focused on Alzheimer's disease, with a small-molecule pipeline that addresses neurodegeneration through a similar mechanism-driven approach.

Broad incumbents

  • Biogen: Established large-cap biopharmaceutical company with multiple approved and late-stage Alzheimer's therapies (e.g., lecanemab partnership with Eisai), representing the dominant incumbent in the neurodegenerative space KeifeRx targets.
  • Cerevel Therapeutics: Larger CNS-focused biopharma developing therapies across multiple neurological indications, representing an established CNS pipeline competitor with broader resources.

Emerging players

  • AC Immune: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Alzheimer's and Parkinson's, with a complementary but partially overlapping pipeline approach.

Others

  • Bristol Myers Squibb: Markets nilotinib (the drug KeifeRx's chemistry builds upon) and is active in neurodegeneration R&D, making it both a potential comparator and a future competitor or partner in the kinase-inhibitor neurodegeneration space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

KeifeRx social profiles

Digital presence

KeifeRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KeifeRx leadership team

Management profile

Number of profiles

Profiles12 records

KeifeRx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KeifeRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KeifeRx

What does KeifeRx do?

KeifeRx develops a pipeline of orally delivered, second-generation small-molecule kinase inhibitors targeting neurodegenerative diseases, with lead asset KFRX03 in Phase 1 for Alzheimer's disease and additional preclinical candidates for Parkinson's disease (KFRX05, KFRX06), ALS (KFRX04), and frontotemporal dementia. The drug candidates are designed to cross the blood-brain barrier, restore autophagy, and simultaneously address neuroinflammation, toxic protein accumulation, and vascular damage. The company intends to commercialize its candidates through licensing or co-development agreements with larger pharmaceutical partners rather than direct sales.

Is KeifeRx a public or private company?

KeifeRx is a private company. It is classified as venture growth investor backed and is currently operating.

When was KeifeRx founded?

KeifeRx was founded in 2017. It employs 1 to 10 people.

Where is KeifeRx based?

KeifeRx is headquartered in Mclean, United States, in the North America region.

How does KeifeRx make money?

One revenue line is on record: pharmaceutical Development and Licensing.

Who are KeifeRx's main competitors?

Direct peers on record are Anavex Life Sciences, Sage Therapeutics, Prothena, Cognition Therapeutics, Denali Therapeutics and Cassava Sciences. Broad incumbents are Biogen and Cerevel Therapeutics. AC Immune is listed as an emerging player. Bristol Myers Squibb is listed as an others.

Does KeifeRx have an API?

No public API is recorded for KeifeRx.

What industry is KeifeRx in?

KeifeRx's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogKeifeRx to Headline Partner Spotlight on Brain Health Innovation at The Third Line Summit, November 19 in Washington, DCKeifeRx will headline a partner spotlight at The Third Line Summit on November 19 in Washington, DC, discussing its disease-modifying medicines for neurodegenerative diseases. The company's drugs restore autophagy and reduce inflammation, with Phase 2 results showing cognitive improvement and 70% fewer falls in Lewy body dementia. Upcoming trials are expected in patients with existing disease.FinancialContent Business PageKeifeRx to Headline Partner Spotlight on Brain Health Innovation at The Third Line Summit, November 19 in Washington, DCKeifeRx will headline a Partner Spotlight at The Third Line Summit on November 19 in Washington, DC, discussing its disease-modifying medicines for neurodegenerative diseases. The company's drugs aim to restore autophagy and reduce inflammation, with Phase 2 results showing cognitive improvement and 70% fewer falls in Lewy body dementia. Upcoming trials are expected in patients with existing disease.EIN PresswireKeifeRx CEO Chris Hoyt to Speak at the 2nd Annual Neuroscience Innovation Partnering & Licensing Summit in BostonKeifeRx CEO Chris Hoyt will speak at the 2nd Annual Neuroscience Innovation Partnering & Licensing Summit in Boston on April 28–29, 2026. He will highlight the company's pipeline of kinase inhibitors, including lead asset KFRX03 for Alzheimer's disease. The company holds an exclusive license to Georgetown University's intellectual property.openPR.comLewy Body Dementia Market: Accelerating Growth and Pipeline Impact by 2034- DelveInsight | Cognition Therapeutics, KeifeRx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition TherapeuticsDelveInsight published a market research report on Lewy Body Dementia, valued at approximately USD 670 million in 2022 and projected to grow significantly through 2034, covering epidemiology trends across the US, EU4, UK, and Japan.Investing.comAmneal Pharmaceuticals stock hits 52-week high at $13.48 By Investing.comAmneal Pharmaceuticals Inc Class A stock reached a 52-week high of $13.48, marking a 56.51% appreciation over the past year and a 68.26% surge over the last six months, reflecting strong investor confidence in the company's market performance. The company, with a $4.2 billion market capitalization and "GREAT" financial health score, also received FDA approvals for two denosumab biosimilars (Boncresa and Oziltus) and announced a research collaboration with KeifeRx for a preclinical Parkinson disease candidate. Revenue grew 9.5% in the most recent reporting period, and analysts forecast the company will be profitable this year with an EPS of $0.82.Investing.comKeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.comKeifeRx, a privately held biotechnology company, has entered into a research collaboration and option agreement with Amneal Pharmaceuticals (NASDAQ:AMRX) to advance KFRX06, a preclinical candidate targeting Parkinson's disease through KeifeRx's LRRK2 inhibitor technology. Financial terms of the agreement were not disclosed, and the collaboration establishes a structured path for potential next-stage development and commercialization pending promising pre-IND results. The article also notes recent Amneal FDA approvals for two denosumab biosimilars and positive interim Phase 4 results for CREXONT, its extended-release Parkinson's treatment.Investing.comKeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.comKeifeRx, a privately held biotechnology company, has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to advance the pre-IND development of KFRX06, a preclinical candidate targeting Parkinson's disease based on KeifeRx's LRRK2 inhibitor technology. Financial terms of the agreement were not disclosed, but Amneal, with a $4.1 billion market capitalization, reported $2.93 billion in revenue over the trailing twelve months with 9.5% growth. The collaboration establishes a structured path for potential next-stage development and commercialization should the pre-IND work yield promising results.Investing.comKeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.comKeifeRx, a privately held biotechnology company, has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to advance pre-IND development of KFRX06, a preclinical LRRK2 inhibitor candidate targeting Parkinson's disease. Amneal, with a market capitalization of $4.1 billion and $2.93 billion in trailing twelve-month revenue, will evaluate the compound for potential future development while KeifeRx conducts research to generate key pre-IND outputs. The collaboration establishes a structured path for potential next-stage development and commercialization, contingent on promising results from the pre-IND work.PR NewswireKeifeRx Appoints Garrett Vygantas, MD, MBA, to Board of DirectorsKeifeRx, a clinical-stage biopharmaceutical company developing tyrosine kinase inhibitors for neurodegenerative and immune diseases, appointed Garrett Vygantas, MD, MBA, to its Board of Directors on February 14, 2023. Dr. Vygantas brings over 20 years of industry, investment, and entrepreneurial experience, including roles as founding Managing Partner of Riverine Ventures and prior positions at Genentech and various life sciences companies. The company stated this appointment comes at an important phase as it advances its pipeline of TKI treatments for conditions including Alzheimer's disease, ALS, and Lewy Body Dementia.PR NewswireKeifeRx to Present at BioFuture 2022KeifeRx announced that its CEO Chris Hoyt will present at BioFuture 2022, scheduled for November 7-9, 2022, at the Lotte New York Palace in New York City. During the conference, the company's management team will host one-on-one meetings with registered investors and pharmaceutical executives to discuss its portfolio of optimized, low-dose, orally-delivered tyrosine kinase inhibitors designed to treat neurodegenerative and immune diseases including Alzheimer's, ALS, and Lewy Body Dementia. The company holds an exclusive license to underlying technology developed by Georgetown University for the use of TKIs in treating neurodegenerative diseases.